To develop protein therapeutics from exogenous sources, it is necessary to mitigate the risks of eliciting an anti-biotherapeutic immune response. A key aspect of the response is the recognition and surface display by antigen-presenting cells of epitopes, short peptide fragments derived from the foreign protein. Thus, developing minimal-epitope variants represents a powerful approach to deimmunizing protein therapeutics. Critically, mutations selected to reduce immunogenicity must not interfere with the protein's therapeutic activity.
Parker, Andrew S.; Zheng, Wei; Griswold, Karl E.; and Bailey-Kellogg, Chris, "Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins" (2010). Open Dartmouth: Faculty Open Access Articles. 569.